🔎 Trials Near Me

Home › Pancreatic Cancer › NCT06388967

Pancreatic Cancer Detection Consortium

RecruitingObservational studyHealthy volunteers welcome

Early Detection of Pancreatic Cancer: Prospective Study

Who can join

Ages 18 and older · All sexes · Healthy volunteers welcome

Full eligibility criteria
Inclusion Criteria:

* Histological diagnosis of pancreatic ductal adenocarcinoma, stages I-IV (TNM classification, 8th edition)
* Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.
* Imaging- or endoscopy-based proof of lack of pancreatic ductal adenocarcinoma at the time of sampling (Non-disease controls)

Exclusion Criteria:

* Lack of written informed consent.

About the study

This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.

What is being tested

Sponsor: City of Hope Medical Center · Participants: 2,000 · Started: Mar 15, 2023

Contact the study team

Official record on ClinicalTrials.gov — NCT06388967

Locations in the U.S.

ArizonaTranslational Genomics Research Institute, Phoenix
CaliforniaCity of Hope Medical Center, Monrovia
IllinoisOSF HealthCare, Peoria
LouisianaOchsner Medical Center, Jefferson
New JerseyAtlantic Health System, Morristown
PennsylvaniaAHN Cancer Institute at Allegheny General Hospital, Pittsburgh
South CarolinaPiedmont Medical Center, Rock Hill
WashingtonMultiCare Cancer Institute - Tacoma General Hospital, Tacoma
WisconsinMedical College of Wisconsin, Milwaukee

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.